drugset
drugset / Trial / NCT00750256

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects

NCT00750256 ↗

Phase 1 Completed 36 enrolled GlaxoSmithKline
RandomizedSingle-groupSingle-blindTreatment

Summary

A first-time in human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1278863A in healthy subjects

Timeline

Start
2008-07-07
Primary completion
2008-12-12
Completion
2008-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK1278863A Small molecule 2 mg Oral
Subject GSK1278863A Small molecule 450 mg Oral

Indications

anemia